VESPER-2 VESPER-2 was a randomized, multicenter, double-blind, 28-week placebo-controlled trial that investigated the efficacy and safety of weekly berobenatide doses in adults with obesity or overweight and type 2 diabetes
however, a dedicated kidney outcome trial with semaglutide was recently stopped early for efficacy and data are awaited in 2024 [8]
travel and/or other support for attending meetings from AstraZeneca and Eli Lilly
This can mean higher costs for patients and fewer choices for physicians
News Release July 10, 2018 Best Chromium Supplements Identified by ConsumerLab White Plains, New York, July 10, 2018 Chromium supplements are promoted to help control blood sugar in people with type 2 diabetes and with weight loss
Additionally, MBC demonstrated a markedly elevated uptake rate in NPCs relative to annulus fibrosus cells and macrophages (Supplementary Fig